Hyderabad, March 11, 2015:
The US Supreme Court has denied certiorari for the generic version of Tamiflu (Oseltamivir Phosphate) oral capsules. It is indicated for treatment of influenza.
The development saw the company’s scrip gaining 5.81 per cent to close the day at Rs. 1,642.80 on the BSE.
Hyderabad-based Natco Pharma partners with Alvogen for marketing of this product in the US.
The denial was issued on Monday in the case of Gilead Sciences Inc, Natco informed the BSE on Tuesday.
Certiorari is a writ seeking judicial review. It is issued by a superior court, directing an inferior court, tribunal or other public authority to send the record of a proceeding for review.
